Sio Gene Therapies Inc. (SIOX) shares have gained 2.61% at $1.9599 in Monday’s premarket session. SIOX stock subtracted -0.52% to finish last trading session at $1.91. The SIOX stock recorded a trading volume of 0.45 million shares, which is below the average daily trading volume published for the last 50 days of 1.34 million shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The shares of SIOX have retreated -5.45% in the last five days; however, they have lost -11.98% over the last one month. The SIOX stock price has shed -5.45% over the last three months and has lost -31.29 percent so far this year. SIOX stock has been rising for receiving Fast Track Designation status for a drug candidate.
Which drug has been awarded fast track?
Sio Gene Therapies consolidates state of the art science with striking creative mind to foster hereditary prescriptions that expect to drastically work on the existences of patients. SIOX ‘s momentum pipeline of clinical-stage competitors incorporates the principal possibly corrective AAV-based quality treatments for GM1 gangliosidosis and Tay-Sachs/Sandhoff sicknesses, which are uncommon and consistently lethal pediatric conditions brought about by single quality insufficiencies.
SIOX is likewise extending the span of quality treatment to exceptionally common conditions like Parkinson’s infection, which influences a great many patients all around the world. Driven by an accomplished group of quality treatment advancement specialists, and upheld by joint efforts with chief scholastic, industry and patient support associations, SIOX is centered around speeding up its up-and-comers through clinical preliminaries to free patients with weakening infections through the groundbreaking force of quality treatments.
Sio Gene Therapies today declared that the U.S. Food and Drug Administration (FDA) has allowed Fast Track Designation to SIOX’s AXO-AAV-GM2. It is SIOX’s investigational quality treatment for the treatment of early childish, late puerile and adolescent beginning Tay-Sachs and Sandhoff sickness. The Fast Track assignment is planned to work with the turn of events and review of the medicine to treat genuine conditions and fill a neglected clinical need.
The FDA’s grant to give AXO-AAV-GM2 gene therapy Fast Track assignment means a significant achievement for SIOX towards fostering a protected and compelling treatment for Tay-Sachs and Sandhoff illnesses, both uncommon and deadly pediatric infections with no supported medicines. This assignment supplements the recently conceded Rare Pediatric Disease and Orphan Drug assignments for AXO-AAV-GM2, alongside comparative assignments for AXO-AAV-GM1 for GM1 gangliosidosis, and SIOX will work intimately with the FDA as it proceed with enlistment in its progressing, enrollment empowering preliminary in Tay-Sachs and Sandhoff sicknesses to carry AXO-AAV-GM2 to patients and families.
SIOX previous award:
SIOX’s AXO-AAV-GM2 has gotten Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the FDA and is the main gene therapy in clinical advancement for all pediatric types of GM2 gangliosidosis. In 2018, Sio Gene Therapies (SIOX) licensed with exclusivity from UMass Chan Medical School for the turn of events and commercialization of quality treatment programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff sicknesses.